Clinical Trials News

REDWOOD CITY, Calif. & SHENZHEN, China--(BUSINESS WIRE)--LTZ announces $38 million financing to advance development of immunotherapy pipeline targeting oncology and autoimmune diseases....

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, earned a Leader designation among contract research organizations (CROs) in the 2026 ISG Provider Lens™ Life Sciences Digital Services report, underscoring the company’s continued investment in digital innovation across the clinical development continuum. The recognition highlights the strength of Thermo Fisher’s PPD™ clinical research business, which is recognized for its capabilities in clinic...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Encoded Therapeutics, Inc. (“Encoded”), a clinical-stage biotechnology company developing precision genetic medicines for severe neurological disorders, today announced that the first patient has been dosed in the pivotal ENDEAVOR Part 2 study of ETX101 for Dravet syndrome, marking an important transition into late-stage clinical development for the program. Encoded has also initiated dosing in the ENDEAVOR Part 1B expansion study in patients aged 4...

PARIS--(BUSINESS WIRE)--Waiv, formerly Owkin Dx, a Paris-based company catalyzing AI precision testing, today announced it has entered a collaboration with Daiichi Sankyo (TSE: 4568) to lead digital pathology biomarker discovery for an antibody-drug conjugate (ADC) program. With deep expertise across diverse pathology and multimodal data, and a global data network spanning academic institutions, hospitals, and laboratories, Waiv has a proven track record delivering AI-powered biomarker solution...

BILLERICA, Mass.--(BUSINESS WIRE)--Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), today announced a collaboration with Tempus AI Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, to broaden access to a novel blood-based biomarker panel designed to improve detection accuracy for Alzheimer’s disease. Through the agreement, Tempus AI will build a Tempus Next care gap program for Alzheimer’s disease blood-based biomarker testing...

BOSTON--(BUSINESS WIRE)--Most Oncology Brands Lose Before Launch Day — New ZoomRx Analysis of 40+ Drugs Quantifies the Awareness Gap That Predicts Commercial Failure....

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--CellCentric, a clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma, today announced the completion of an oversubscribed $220 million Series D financing. The financing was led by specialist investor Venrock Healthcare Capital Partners, with participation from a strong syndicate of new and existing investors. Proceeds will support the advancement of inobrodib thro...

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., the leading technology platform for agentic AI clinical development, today announced that its CEO and co-founder, Dr. Michelle Longmire, will be one of three international guest speakers at Japan’s largest pharmaceutical conference, Ubie Pharma Summit (May 13-14, 2026). Longmire will be speaking at the fifth annual event along with Justin Chen, MD, Clinical Specialist at Google for Health, and John Halamka, MD, President of Mayo Clinic Platform....

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter ended March 31, 2026, and provide an update on recent developments, on May 13, 2026. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on May 13, 2026. A live webcast of the call will be available on the Compass P...

LONDON--(BUSINESS WIRE)--Calla Lily Clinical Care, a women’s health-focused medical technology company, today announced dosing of the first patients in the FREEDOM clinical trial. The study, funded by the National Institute for Health and Care Research (NIHR), is evaluating 400mg progesterone Callavid® in patients diagnosed with luteal phase insufficiency, a condition where progesterone levels may be too low to support early pregnancy, increasing risk of infertility and recurrent miscarriage. C...